We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PLMR:NASDAQPalomar Holdings, Inc. Analysis

Data as of 2026-06-03 - not real-time

$102.28

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Palomar Holdings (PLMR) is trading at $102.28, far beneath its DCF‑derived fair value of $711 and the median analyst target of $156, suggesting a sizable upside. The stock shows an RSI of 28, indicating oversold conditions, while the 20‑day SMA (≈$110.6) sits above the current price, confirming short‑term bearish pressure. Despite a bearish MACD and decreasing volume, the company posted a 59.7% revenue surge YoY, a robust operating margin of 20.3%, and a forward EPS growth trajectory that lifts the forward PE to just 9.1. The balance sheet reflects modest leverage (debt‑to‑equity ~31) and a low beta of 0.31, but volatility remains high at ~32% over 30 days, and the max drawdown exceeds 40%.
Recent earnings beats, an expanded product line via the Gray Surety acquisition, and a newly announced buyback program reinforce the fundamental narrative. With no dividend, the focus remains on earnings reinvestment and growth. Overall, the technical downside appears temporary against a backdrop of strong profitability, attractive valuation gaps, and a clear upside potential.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Oversold RSI suggesting potential rebound
  • Current price near key support at $100.81
  • Bearish MACD and decreasing volume indicating short‑term pressure

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Significant valuation upside versus DCF and analyst targets
  • Strong revenue and EPS growth with expanding specialty lines
  • Buyback announcement and recent earnings beat boosting confidence

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Sustainable profitability (ROE ~22.5%) and low beta
  • Strategic acquisition diversifying catastrophe exposure
  • Long‑term valuation gap and resilient cash flow generation

Key Metrics & Analysis

Financial Health

Revenue Growth59.70%
Profit Margin20.11%
P/E Ratio14.3
ROE22.53%
ROA5.31%
Debt/Equity31.01
P/B Ratio2.8
Op. Cash Flow$369.0M
Free Cash Flow$528.4M
Industry P/E16.5

Technical Analysis

TrendBearish
RSI28.1
Support$100.81
Resistance$118.27
MA 20$110.61
MA 50$119.08
MA 200$121.88
MACDBearish
VolumeDecreasing
Fear & Greed Index92.84

Valuation

Fair Value$711.02
Target Price$154.17
Upside/Downside50.74%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta0.31
Volatility31.79%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.